vs
Side-by-side financial comparison of BANCFIRST CORP (BANF) and Vericel Corp (VCEL). Click either name above to swap in a different company.
BANCFIRST CORP is the larger business by last-quarter revenue ($181.0M vs $92.9M, roughly 1.9× Vericel Corp). BANCFIRST CORP runs the higher net margin — 32.9% vs 25.0%, a 7.9% gap on every dollar of revenue. On growth, Vericel Corp posted the faster year-over-year revenue change (23.3% vs 11.1%). BANCFIRST CORP produced more free cash flow last quarter ($237.0M vs $12.8M). Over the past eight quarters, Vericel Corp's revenue compounded faster (34.6% CAGR vs 9.5%).
BancFirst Corporation is an Oklahoma-based financial services holding company. The company operates three subsidiary banks, BancFirst, an Oklahoma state-chartered bank; and Pegasus Bank and Worthington Bank, both Texas state-chartered banks.
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
BANF vs VCEL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $181.0M | $92.9M |
| Net Profit | $59.5M | $23.2M |
| Gross Margin | — | 78.7% |
| Operating Margin | 41.6% | 24.1% |
| Net Margin | 32.9% | 25.0% |
| Revenue YoY | 11.1% | 23.3% |
| Net Profit YoY | 5.3% | 17.3% |
| EPS (diluted) | $1.75 | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $181.0M | $92.9M | ||
| Q3 25 | $175.5M | $67.5M | ||
| Q2 25 | $169.3M | $63.2M | ||
| Q1 25 | $164.8M | $52.6M | ||
| Q4 24 | $162.9M | $75.4M | ||
| Q3 24 | $163.7M | $57.9M | ||
| Q2 24 | $153.8M | $52.7M | ||
| Q1 24 | $151.0M | $51.3M |
| Q4 25 | $59.5M | $23.2M | ||
| Q3 25 | $62.7M | $5.1M | ||
| Q2 25 | $62.3M | $-553.0K | ||
| Q1 25 | $56.1M | $-11.2M | ||
| Q4 24 | $56.5M | $19.8M | ||
| Q3 24 | $58.9M | $-901.0K | ||
| Q2 24 | $50.6M | $-4.7M | ||
| Q1 24 | $50.3M | $-3.9M |
| Q4 25 | — | 78.7% | ||
| Q3 25 | — | 73.5% | ||
| Q2 25 | — | 73.7% | ||
| Q1 25 | — | 69.0% | ||
| Q4 24 | — | 77.6% | ||
| Q3 24 | — | 71.9% | ||
| Q2 24 | — | 69.5% | ||
| Q1 24 | — | 68.9% |
| Q4 25 | 41.6% | 24.1% | ||
| Q3 25 | 45.0% | 5.1% | ||
| Q2 25 | 47.1% | -3.2% | ||
| Q1 25 | 43.1% | -24.3% | ||
| Q4 24 | 44.2% | 24.5% | ||
| Q3 24 | 45.2% | -4.3% | ||
| Q2 24 | 42.4% | -11.5% | ||
| Q1 24 | 42.5% | -10.7% |
| Q4 25 | 32.9% | 25.0% | ||
| Q3 25 | 35.7% | 7.5% | ||
| Q2 25 | 36.8% | -0.9% | ||
| Q1 25 | 34.0% | -21.4% | ||
| Q4 24 | 34.7% | 26.3% | ||
| Q3 24 | 36.0% | -1.6% | ||
| Q2 24 | 32.9% | -8.9% | ||
| Q1 24 | 33.3% | -7.5% |
| Q4 25 | $1.75 | $0.46 | ||
| Q3 25 | $1.85 | $0.10 | ||
| Q2 25 | $1.85 | $-0.01 | ||
| Q1 25 | $1.66 | $-0.23 | ||
| Q4 24 | $1.68 | $0.40 | ||
| Q3 24 | $1.75 | $-0.02 | ||
| Q2 24 | $1.51 | $-0.10 | ||
| Q1 24 | $1.50 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.9B | $354.6M |
| Total Assets | $14.8B | $488.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $137.5M | ||
| Q3 25 | — | $135.4M | ||
| Q2 25 | — | $116.9M | ||
| Q1 25 | — | $112.9M | ||
| Q4 24 | — | $116.2M | ||
| Q3 24 | — | $101.7M | ||
| Q2 24 | — | $102.5M | ||
| Q1 24 | — | $110.6M |
| Q4 25 | $1.9B | $354.6M | ||
| Q3 25 | $1.8B | $321.9M | ||
| Q2 25 | $1.7B | $306.8M | ||
| Q1 25 | $1.7B | $295.5M | ||
| Q4 24 | $1.6B | $292.0M | ||
| Q3 24 | $1.6B | $257.5M | ||
| Q2 24 | $1.5B | $243.0M | ||
| Q1 24 | $1.5B | $233.9M |
| Q4 25 | $14.8B | $488.0M | ||
| Q3 25 | $14.2B | $453.3M | ||
| Q2 25 | $14.0B | $435.6M | ||
| Q1 25 | $14.0B | $424.6M | ||
| Q4 24 | $13.6B | $432.7M | ||
| Q3 24 | $13.3B | $390.4M | ||
| Q2 24 | $12.7B | $376.8M | ||
| Q1 24 | $12.6B | $356.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $285.3M | $15.0M |
| Free Cash FlowOCF − Capex | $237.0M | $12.8M |
| FCF MarginFCF / Revenue | 130.9% | 13.8% |
| Capex IntensityCapex / Revenue | 26.7% | 2.4% |
| Cash ConversionOCF / Net Profit | 4.79× | 0.65× |
| TTM Free Cash FlowTrailing 4 quarters | $430.7M | $24.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.3M | $15.0M | ||
| Q3 25 | $75.4M | $22.1M | ||
| Q2 25 | $78.1M | $8.2M | ||
| Q1 25 | $77.0M | $6.6M | ||
| Q4 24 | $261.2M | $22.2M | ||
| Q3 24 | $77.6M | $10.2M | ||
| Q2 24 | $100.2M | $18.5M | ||
| Q1 24 | $66.3M | $7.2M |
| Q4 25 | $237.0M | $12.8M | ||
| Q3 25 | $63.7M | $19.5M | ||
| Q2 25 | $64.4M | $81.0K | ||
| Q1 25 | $65.6M | $-7.6M | ||
| Q4 24 | $224.5M | $8.5M | ||
| Q3 24 | $72.4M | $-9.2M | ||
| Q2 24 | $94.1M | $1.8M | ||
| Q1 24 | $56.1M | $-6.8M |
| Q4 25 | 130.9% | 13.8% | ||
| Q3 25 | 36.3% | 28.8% | ||
| Q2 25 | 38.0% | 0.1% | ||
| Q1 25 | 39.8% | -14.5% | ||
| Q4 24 | 137.8% | 11.2% | ||
| Q3 24 | 44.2% | -15.9% | ||
| Q2 24 | 61.2% | 3.4% | ||
| Q1 24 | 37.1% | -13.3% |
| Q4 25 | 26.7% | 2.4% | ||
| Q3 25 | 6.7% | 3.9% | ||
| Q2 25 | 8.1% | 12.9% | ||
| Q1 25 | 6.9% | 27.0% | ||
| Q4 24 | 22.5% | 18.3% | ||
| Q3 24 | 3.2% | 33.5% | ||
| Q2 24 | 3.9% | 31.8% | ||
| Q1 24 | 6.8% | 27.3% |
| Q4 25 | 4.79× | 0.65× | ||
| Q3 25 | 1.20× | 4.35× | ||
| Q2 25 | 1.25× | — | ||
| Q1 25 | 1.37× | — | ||
| Q4 24 | 4.62× | 1.12× | ||
| Q3 24 | 1.32× | — | ||
| Q2 24 | 1.98× | — | ||
| Q1 24 | 1.32× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BANF
Segment breakdown not available.
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
